Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Gastroenterology. 2019 Dec;157(6):1584-1598. doi: 10.1053/j.gastro.2019.09.002. Epub 2019 Sep 10.
BACKGROUND & AIMS: T-regulatory (Treg) cells suppress the immune response to maintain homeostasis. There are 2 main subsets of Treg cells: FOXP3 (forkhead box protein 3)-positive Treg cells, which do not produce high levels of effector cytokines, and type 1 Treg (Tr1) cells, which are FOXP3-negative and secrete interleukin (IL) 10. IL10 is an anti-inflammatory cytokine, so Tr1 cells might be used in the treatment of inflammatory bowel diseases. We aimed to develop methods to isolate and expand human Tr1 cells and define their functions.
We obtained blood and colon biopsy samples from patients with Crohn's disease or ulcerative colitis or healthy individuals (controls). CD4 T cells were isolated from blood samples and stimulated with anti-CD3 and anti-CD28 beads, and Tr1 cells were purified by using an IL10 cytokine-capture assay and cell sorting. FOXP3-positive Treg cells were sorted as CD4CD25CD127 cells from unstimulated cells. Tr1 and FOXP3-positive Treg cells were expanded, and phenotypes and gene expression profiles were compared. T cells in peripheral blood mononuclear cells from healthy donors were stimulated with anti-CD3 and anti-CD28 beads, and the suppressive abilities of Tr1 and FOXP3-positive Treg cells were measured. Human colon organoid cultures were established, cultured with supernatants from Tr1 or FOXP3-positive cells, and analyzed by immunofluorescence and flow cytometry. T84 cells (human colon adenocarcinoma epithelial cells) were incubated with supernatants from Tr1 or FOXP3-positive cells, and transepithelial electrical resistance was measured to determine epithelial cell barrier function.
Phenotypes of Tr1 cells isolated from control individuals vs patients with Crohn's disease or ulcerative colitis did not differ significantly after expansion. Tr1 cells and FOXP3-positive Treg cells suppressed proliferation of effector T cells, but only Tr1 cells suppressed secretion of IL1B and tumor necrosis factor from myeloid cells. Tr1 cells, but not FOXP3-positive Treg cells, isolated from healthy individuals and patients with Crohn's disease or ulcerative colitis secreted IL22, which promoted barrier function of human intestinal epithelial cells. Tr1 cell culture supernatants promoted differentiation of mucin-producing goblet cells in intestinal organoid cultures.
Human Tr1 cells suppress proliferation of effector T cells (adaptive immune response) and production of IL1B and TNF by myeloid cells (inmate immune response). They also secrete IL22 to promote barrier function. They might be developed as a cell-based therapy for intestinal inflammatory disorders.
调节性 T 细胞(Treg)抑制免疫反应以维持体内平衡。Treg 细胞有 2 个主要亚群:FOXP3(叉头框蛋白 3)阳性 Treg 细胞,其不产生高水平的效应细胞因子;以及 1 型 Treg(Tr1)细胞,其 FOXP3 阴性并分泌白细胞介素(IL)10。IL10 是一种抗炎细胞因子,因此 Tr1 细胞可能用于治疗炎症性肠病。本研究旨在开发分离和扩增人 Tr1 细胞的方法,并定义其功能。
我们从克罗恩病或溃疡性结肠炎患者或健康个体(对照)中获得血液和结肠活检样本。从血液样本中分离 CD4 T 细胞,用抗 CD3 和抗 CD28 珠刺激,并用 IL10 细胞因子捕获测定和细胞分选法纯化 Tr1 细胞。FOXP3 阳性 Treg 细胞从未刺激的细胞中作为 CD4CD25CD127 细胞进行分选。扩增 Tr1 和 FOXP3 阳性 Treg 细胞,并比较其表型和基因表达谱。用抗 CD3 和抗 CD28 珠刺激健康供体外周血单核细胞中的 T 细胞,测量 Tr1 和 FOXP3 阳性 Treg 细胞的抑制能力。建立人结肠类器官培养物,用 Tr1 或 FOXP3 阳性细胞的上清液培养,并通过免疫荧光和流式细胞术进行分析。用 Tr1 或 FOXP3 阳性细胞的上清液孵育 T84 细胞(人结肠腺癌细胞),测量跨上皮电阻以确定上皮细胞屏障功能。
与克罗恩病或溃疡性结肠炎患者相比,来自对照个体的 Tr1 细胞在扩增后其表型无显著差异。Tr1 细胞和 FOXP3 阳性 Treg 细胞抑制效应 T 细胞的增殖,但只有 Tr1 细胞抑制髓样细胞分泌 IL1B 和肿瘤坏死因子。来自健康个体和克罗恩病或溃疡性结肠炎患者的 Tr1 细胞均分泌 IL22,可促进人肠道上皮细胞的屏障功能,而仅 FOXP3 阳性 Treg 细胞具有这种作用。Tr1 细胞培养上清液促进肠类器官培养物中粘蛋白产生的杯状细胞的分化。
人 Tr1 细胞抑制效应 T 细胞(适应性免疫反应)的增殖和髓样细胞(固有免疫反应)产生的 IL1B 和 TNF。它们还分泌 IL22 以促进屏障功能。它们可能被开发为治疗肠道炎症性疾病的细胞疗法。